A Mass Spectrometry-Based Panel of Nine Thyroid Hormone Metabolites in Human Serum

Abstract

BACKGROUND: While thyroxine (T4), 3,3’,5-triiodothy-ronine (T3), and 3,3’,5’-triiodothyronine (rT3) have routine methods available for evaluating patients with suspected thyroid disease, appropriate methods for the measurement of other thyroid hormone metabolites (THMs) are lacking. The effects of other iodothyronines or iodothyroacetic acids are therefore less explored. To better understand the (patho)physiological role of THMs, a robust method to measure iodothyronines and iodothyroacetic acids in serum in a single analysis is needed, including associated reference intervals. METHODS: Clinical and Laboratory Standards Institute guidelines, European Medicines Agency guidelines, and the National Institute of Standards and Technology protocol were used for the method validation and reference intervals. Reference intervals were determined in 132 healthy males and 121 healthy females. Serum samples were deproteinized with acetonitrile, followed by anion-exchange solid phase extraction and analysis with LC-MS/MS, using eight 13C6-internal standards RESULTS: The analytical method validation was performed for all nine THMs. Reference intervals (2.5th to 97.5th percentile) were determined for L-thyronine (4.9–11.3 ng/dL), 3-monoiodothyronine (0.06 –0.41 ng/ dL), 3,5-diiodothyronine (<0.13 ng/dL), 3,3’-diiodo-thyronine (0.25–0.77 ng/dL), T3 (66.4–129.9 ng/dL), rT3 (15.0–64.1 ng/dL), T4 (4.3–10.0 mg/dL), triac/ 3,3’,5-triiodothyroacetic acid (not detected), and tetrac/ 3,3’,5,5’-tetraiodothyroacetic acid (2.2–27.2 ng/dL). CONCLUSIONS: A broad dynamic concentration range exists among the nine THMs. This method should help to develop a better understanding of the clinical relevance of other THMs, as well as an understanding of thyroid hormone metabolism in health and disease.